Analysts’ Viewpoint on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Scenario
Rise in inflammatory bowel disease (IBD) patient pool, approval of new biologic drugs for IBD, novel drugs pipeline, and increase in demand for application of IBD treatment in developing countries are anticipated to propel the global IBD (ulcerative colitis and Crohn’s disease) treatment market. However, high costs could hamper the sales of therapeutics. Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in TNF inhibitors is expected to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe ulcerative colitis. Furthermore, development of anti-adhesion molecules is likely to boost the adoption of integrin antagonists.
Rise in prevalence of inflammatory bowel disease (IBD) across the globe is driving the global IBD (Ulcerative Colitis & Crohn’s Disease) treatment market. IBD is a group of gastrointestinal inflammatory diseases that primarily comprises ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Ulcerative colitis disease mostly affects the inner lining of large intestines and causes inflammation and sores in the colon and rectum. Ulcerative colitis is a more commonly observed disease than Crohn’s disease. It can affect any part of the gastrointestinal tract, starting from the mouth to the small intestine and anus. Common symptoms of IBD include chronic pain and cramps in the abdomen, persistent diarrhea, occasional rectal bleeding, and fever. The exact cause of inflammatory bowel disease is not well understood, and high prevalence and incidence rates of these diseases have been observed in developed countries.
Innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are the factors driving the global IBD treatment market. Growth in sales of IBD drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars – adalimumab and infliximab – for the treatment of Ulcerative Colitis. Biopharmaceutical companies have made significant investments in R&D activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize during the forecast period. Furthermore, high prevalence and incidence of IBD in countries in the West is anticipated to augment the global market. According to a report, around 2.5 million people in the U.S. suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the U.S. population is expected to rise to around 3.5 million by 2030. Similarly, data suggests that the incidence and prevalence of inflammatory bowel diseases [IBD] is still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020.
The outbreak of COVID-19 has had a negative effect on the global IBD treatment market, as many governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Lockdowns in several countries, travel restrictions, and closure of the diagnostic centers led to a substantial decline in overall diagnostic procedures and treatments. According to two research letters published in JAMA Internal Medicine, there were 6,411 non-COVID-19 hospitalizations, including pediatric inflammatory bowel diseases, in 2019. This data is based on admissions to four hospitals in New York. However, the total admission in 2020 was 3,657 for the same conditions, while the overall decline of non-patients was around 40%. Players operating in the market witnessed a decline in revenue during the financial year 2020. For instance, Pfizer, Inc. registered a decline of -3.5% in revenue generated from its inflammation & immunology segment in 2020. Nevertheless, the market has seen a recovery from COVID-19 impact due to the easing of restrictions by various governments across the globe. Demand for drugs increased in 2021 due to the rise in diagnosis rate of diseases. Leading companies in the market reported an increase in revenue during 2021. Hence, the future IBD treatment market is anticipated to witness recovery at pre-pandemic levels.
The TNF inhibitors segment is projected to lead the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. The segment's large market share can be ascribed to superior efficacy and safety of drugs in this class in the treatment of IBD, increase in adoption of biologics and biosimilars in countries in the West such as the U.K., France, Germany, and the U.S., and high cost of these drugs. Furthermore, rise in adoption of biologic drugs for the treatment of IBD and high clinical R&D budgets contributed to the TNF inhibitors segment's large share in 2021. TNF inhibitors are used as the second line of treatment when other medications do not work effectively to relieve symptoms of IBD. High adoption of TNF inhibitors owing to promising therapeutic results for the management of IBD, high per capita health care expenditure, and increase in number of hospitalizations can be ascribed to the TNF inhibitors segment's significant market share in 2021.
The ulcerative colitis segment accounted for the largest share of the global market in 2021. The trend is expected to continue during the forecast period. High prevalence and incidence of ulcerative colitis in Europe and North America, increase in awareness about the disease, and rise in number of hospitalization cases of ulcerative colitis are the key factors driving the ulcerative colitis segment. An article published on NCBI (2020) stated that ulcerative colitis has an incidence of 9 to 20 cases per 100,000 per year. Its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe. Similarly, in Canada, more than 104,000 people are living with ulcerative colitis and nearly 4,500 cases of ulcerative colitis are diagnosed every year. Furthermore, a recent report suggests that 600,000 to 900,000 people in the U.S. have ulcerative colitis.
The retail pharmacies segment dominated the global market in terms of market share in 2021 due to the rise in sale of biologic drugs through retail pharmacy chains in the U.S. Biologic drugs accounted for major share of the IBD treatment market in the U.S. in 2021. Easy availability of drugs such as corticosteroids, Aminosalicylates, and biologics at retail pharmacy stores and usage of these drugs, except biologics, as the first line of treatment is propelling the retail pharmacies segment. Moreover, retail pharmacies are considered the first point of contact for self-medication. In 2019, India had more than 800,000 pharmacies; retail pharmacies are still the dominant medical distribution channel. Hence, presence of a large existing base of retail pharmacy stores in countries such as India, China, the U.S., and Canada is likely to augment the retail pharmacies segment during the forecast period.
North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2021. It is projected to gain major market share by the end of 2031. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of ulcerative colitis and Crohn’s disease in the U.S. and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors. Additionally, strong product pipeline of key players is projected to drive the global IBD (ulcerative colitis and Crohn’s disease) treatment market in the region.
Asia Pacific is projected to be the fastest growing market for IBD (ulcerative colitis and Crohn’s disease) treatment during the forecast period. Japan dominated the IBD treatment market in the region in 2021. The IBD (ulcerative colitis and Crohn’s disease) treatment market in China is anticipated to grow at a high CAGR during the forecast period. The IBD (ulcerative colitis and Crohn’s disease) treatment market in Latin America and Middle East & Africa is likely to expand at a decent CAGR during the forecast period due to the increase in IBD patient pool and rise in focus of manufacturers on the development of novel therapeutics.
Each of these players has been profiled in the IBD (ulcerative colitis & Crohn’s disease) treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size Value in 2021 | US$ 17.3 Bn |
| Market Forecast Value in 2031 | More than US$ 34.22 Bn |
| Compound Annual Growth Rate (CAGR) | 6.8% |
| Forecast Period | 2022-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global IBD (ulcerative colitis & Crohn’s disease) treatment market was valued at US$ 17.3 Bn in 2021
The global IBD (ulcerative colitis & Crohn’s disease) treatment market is projected to reach more than US$ 34.22 Bn by 2031
The global IBD (ulcerative colitis & Crohn’s disease) treatment market is anticipated to grow at a CAGR of 6.8% from 2022 to 2031
Increase in incidence of ulcerative colitis and Crohn’s disease is driving the global IBD (ulcerative colitis & Crohn’s disease) treatment market
North America is expected to account for major share of the global IBD (ulcerative colitis & Crohn’s disease) treatment market during the forecast period
Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Health Companies, Inc., Allergan plc., Takeda Pharmaceutical Company Limited, AbbVie, Inc., Novartis AG, and UCB, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. TNF Inhibitors
6.3.2. Aminosalicylates
6.3.3. Integrin Antagonists
6.3.4. Corticosteroids
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2017-2031
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. TNF Inhibitors
10.2.2. Aminosalicylates
10.2.3. Integrin Antagonists
10.2.4. Corticosteroids
10.2.5. Others
10.3. Market Value Forecast, by Disease Indication, 2017-2031
10.3.1. Ulcerative Colitis
10.3.2. Crohn’s Disease
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Disease Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. TNF Inhibitors
11.2.2. Aminosalicylates
11.2.3. Integrin Antagonists
11.2.4. Corticosteroids
11.2.5. Others
11.3. Market Value Forecast, by Disease Indication, 2017-2031
11.3.1. Ulcerative Colitis
11.3.2. Crohn’s Disease
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Disease Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. TNF Inhibitors
12.2.2. Aminosalicylates
12.2.3. Integrin Antagonists
12.2.4. Corticosteroids
12.2.5. Others
12.3. Market Value Forecast, by Disease Indication, 2017-2031
12.3.1. Ulcerative Colitis
12.3.2. Crohn’s Disease
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Disease Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. TNF Inhibitors
13.2.2. Aminosalicylates
13.2.3. Integrin Antagonists
13.2.4. Corticosteroids
13.2.5. Others
13.3. Market Value Forecast, by Disease Indication, 2017-2031
13.3.1. Ulcerative Colitis
13.3.2. Crohn’s Disease
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Disease Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. TNF Inhibitors
14.2.2. Aminosalicylates
14.2.3. Integrin Antagonists
14.2.4. Corticosteroids
14.2.5. Others
14.3. Market Value Forecast, by Disease Indication, 2017-2031
14.3.1. Ulcerative Colitis
14.3.2. Crohn’s Disease
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Disease Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Allergan plc
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Bausch Health Companies, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Biogen, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Celltrion Healthcare Co., Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Janssen Biotech, Inc. (Johnson & Johnson
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Pfizer, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Takeda Pharmaceutical Company Limited
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. UCB, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Other Prominent Players
List of Tables
Table 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 03: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 07: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 08: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 11: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 12: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 15: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 16: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 19: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 20: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 23: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Market Value Share, by Drug Class, 2021
Figure 03: Market Value Share, by Disease Indication, 2021
Figure 04: Market Value Share, by Distribution Channel, 2021
Figure 05: Market Value Share, by Region, 2021
Figure 06: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 07: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031
Figure 08: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017-2031
Figure 09: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Aminosalicylates, 2017-2031
Figure 10: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Integrin Antagonists, 2017-2031
Figure 11: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2031
Figure 12: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2031
Figure 13: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
Figure 14: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031
Figure 15: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ulcerative Colitis, 2017-2031
Figure 16: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Crohn’s Disease, 2017-2031
Figure 17: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 18: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031
Figure 19: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2031
Figure 20: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2031
Figure 21: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027
Figure 22: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Region, 2021 and 2031
Figure 23: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Region, 2017-2031
Figure 24: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 25: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 26: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2017-2031
Figure 27: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 28: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
Figure 29: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 30: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 31: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
Figure 32: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 33: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 34: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 35: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 36: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 37: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
Figure 38: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 39: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 40: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
Figure 41: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 42: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 43: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 44: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2017-2031
Figure 45: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
Figure 47: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 48: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031
Figure 49: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031
Figure 50: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031
Figure 51: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 52: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 53: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 54: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 55: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
Figure 56: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 57: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 58: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
Figure 59: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 60: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 61: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 62: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2017-2031
Figure 63: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 64: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
Figure 65: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 66: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031
Figure 67: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031
Figure 68: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market
